APM
SNDX icon

Avidity Partners Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Avidity Partners Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-340,000
Closed -$3.18M – 63
2025
Q2 		$3.18M Sell
340,000
-60,000
-15% -$660K 0.63% 41
2025
Q1 		$4.91M Buy
+400,000
New +$5.64M 0.94% 39

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Avidity Partners Management's SNDX Position: Q3 2025 in Review

Avidity Partners Management sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 150,000 shares — an estimated $1.4M sold.

Avidity Partners Management first reported a position in SNDX in Q2 2020 and held it in 21 quarters. The position peaked at $149M in Q4 2022. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

  • Avidity Partners Management reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Avidity Partners Management sold 150,000 Syndax Pharmaceuticals shares in Q3 2025, an estimated $1.4M.
  • Avidity Partners Management first reported a position in Syndax Pharmaceuticals in Q2 2020 and held it in 21 quarters.
  • Avidity Partners Management's Syndax Pharmaceuticals position peaked at $149M in Q4 2022.
  • 227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Avidity Partners Management's 13F filing for Q3 2025, filed 14 Nov 2025.